Puriblood Medical Co., Ltd. (6847.TWO)

TWD 83.6

(0.24%)

Market Cap (In TWD)

1.18 Billion

Revenue (In TWD)

125.26 Million

Net Income (In TWD)

-51.59 Million

Avg. Volume

14.6 Thousand

Currency
TWD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
82.7-134.0
PE
-25.96
EPS
-3.22
Beta Value
-0.042
ISIN
TW0006847007
CUSIP
-
CIK
-
Shares
14230000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Dr. Luke Chen
Employee Count
-
Website
https://www.puriblood.com
Ipo Date
2021-11-05
Details
Puriblood Medical Co., Ltd. develops and sells blood cell separation products in Taiwan. The company offers leukocyte reduction filters for red blood cells, platelets, and whole blood, as well as real-time filtration sets for whole blood. It also offers Devin blood fractionation membrane filters and Minipuri cell screening syringe filters. In addition, the company develops P-Tex Technology, which is composed by bio-inspired molecular formula – zwitterionic copolymer structure. Puriblood Medical Co., Ltd. was founded in 2016 and is based in Hsinchu City, Taiwan.